Within the tisa-cel-treated patients there was a trend towards a better treatment outcome in patients carrying the CTLA4 rs2317875, and a significant association of CTLA4 genetic background with IL-6 peak levels and CRS rates, but not with CAR-T cell prevalence or persistence. This evidence concerns the gene CTLA4 and congenital rubella syndrome.